ELEGANCE Registry Reports 12-Month Eluvia DES Outcomes in Complex PAD

October 16, 2026—The ELEGANCE registry, which focuses on historically underrepresented populations to generate real-world evidence, evaluated endovascular treatment of peripheral artery disease (PAD) with the Ranger drug-coated balloon or Eluvia drug-eluting stent (DES; both Boston Scientific Corporation). The 12-month outcomes for patients with complex femoropopliteal lesions treated with DES were presented by Eric A. Secemsky, MD, MSc, in a late-breaking trials session at VIVA 2026, the Vascular InterVentional Advances conference.

The findings presented at VIVA focused on patients with diabetes mellitus, chronic total occlusions (CTOs), long lesions ≥ 150 mm, and/or moderate to severe calcification.

The prospective ELEGANCE registry included 382 DES-treated patients with 405 femoropopliteal lesions who completed the 12-month follow-up window. Among the patients, 55.7% had medically treated diabetes mellitus (n = 195), 61.5% had CTOs (n = 240), 33.3% had long lesions ≥ 150 mm (n = 135), and 63.9% had moderate to severe calcification (n = 241). At baseline, 36.2% of patients had chronic limb-threatening ischemia (Rutherford class 4-6).

VIVA reported that Kaplan-Meier estimates at 12 months showed primary patency of 93.2% ± 1.3%, freedom from clinically driven target lesion revascularization (CD-TLR) of 94.1% ± 1.2%, and freedom from major (above-ankle) amputation of 99.4% ± 0.4%.

Across the complex disease subgroups, primary patency ranged from 93.6% to 94.2%, freedom from CD-TLR ranged from 94.2% to 95.9%, and freedom from major amputation ranged from 99.1% to 99.6%.

The investigators concluded in the VIVA press release that patients treated with DES for femoropopliteal lesions had favorable 12-month outcomes, including those with complex disease characteristics historically associated with higher rates of restenosis.

Previous 12-month findings from the ELEGANCE registry were presented by Jay Giri, MD, at VIVA 2024.